Treatment of multidrug-resistant tuberculosis: Definition of the outcome 'failure'

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 1, 2011, Pages 4-5

  Chiang, Chen Yuan ^a   Van Deun, A ^a   Trebucq A ^a   Heldal, E ^a   Caminero, J A ^a   Ait Khaled N ^a  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; BACTERIUM CULTURE; CLINICAL PRACTICE; DECISION MAKING; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY; SPUTUM CULTURE; SPUTUM SMEAR; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; BACTERIOLOGICAL TECHNIQUES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; HUMANS; TERMINOLOGY AS TOPIC; TIME FACTORS; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 78650159754     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (12)

1. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
2. Laserson K F, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645. (Pubitemid 40826156)
3. Chiang C-Y, Caminero J, Enarson D A. Reporting on multidrug-resistant tuberculosis: a proposed definition for the treatment outcome 'failed'. Int J Tuberc Lung Dis 2009; 13: 548-550.
4. Aber V R, Allen B W, Mitchison D A, Ayuma P, Edwards E A, Keyes A B. Quality control in tuberculosis bacteriology. 1. Laboratory studies on isolated positive cultures and the efficiency of direct smear examination. Tubercle 1980; 61: 123-133.
5. Chiang C-Y, Enarson D A, Yu M-C, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-year follow-up study. Eur Respir J 2006; 28: 980-985.
6. Van Deun A, Aung K J M, Salim M A H, et al. Short, highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
7. Leimane V, Riekstina V, Holtz T H, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326. (Pubitemid 40139109)
8. Holtz T H, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006; 144: 650-659. (Pubitemid 46780649)
9. Migliori G B, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-626.
10. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871-881.
11. Jacobson K R, Tierney D B, Jeon C Y, Mitnick C D, Murray M B. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
12. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8: 1382-1384.